Insider buying last 90 days
No open-market insider purchases were filed for KVUE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Kenvue closes at $17.81, down 0.3%, sitting between its 50-day average of $18.91 and 200-day average of $18.01. The GekkoIndex reads 69.9, placing the stock in the Accumulation zone, while the gap to Gekko Fair Value of $23.05 stands at -22.7%. Over the past year the stock is down 2.9%, with a six-month return of 2.2% but a one-month decline of 6.9%.
The week's activity centers on Kimberly-Clark's proposed acquisition of Kenvue, valued at $40 billion in some reports and $48.7 billion in another, with Kimberly-Clark preparing concessions to satisfy European Union antitrust regulators ahead of a preliminary review set to conclude on 29 September. The deal has already gained approval in Australia. Alongside the deal news, several institutional filings show mixed positioning: Corient Private Wealth LP cut its stake by 26.5% during the second quarter, while Bank of America Corp DE took a new position of 14,401,068 shares valued at approximately $275.2 million, and HBK Investments L P raised its holding by 33.3% to 28 million shares worth about $535.1 million.
Kenvue's next earnings report is scheduled for 2 November, 43 days away and outside a typical 20-trading-day holding window; the prior report on 6 August showed EPS of $0.31 against a $0.32 estimate, with a -2.2% reaction. Seasonality over three years shows an average -9.7% return across the next 20 trading days, with zero positive occurrences in that span. Analyst coverage from 7 firms includes 1 buy and 6 hold ratings, with a consensus target of $19.50.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Kenvue scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Averages disagree
Close $17.81 sits between the 50-day ($18.91) and 200-day ($18.01) averages, or the averages disagree.
See the chart69.9, Accumulation
Reading 69.9 is in the Accumulation zone.
See the GekkoIndex22.7% below
Price is 22.7% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 43 days
Next report Nov 2, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings−9.7% on average
From this point in the calendar, the next 20 trading days averaged −9.7% over 3 years, rising in 0 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Kenvue closed at $17.81 on Sep 18, 2026, −2.9% over the past year, inside a 52-week range of $14.02 to $20.13.
Use the left and right arrow keys to read daily values.
Put KVUE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Kenvue sells everyday health and personal-care items to households, built around familiar name brands. Shoppers know it for pain relievers, allergy and cold remedies, skin creams, oral-care items and baby products rather than for a single flagship line.
The business is split into three groups. One line handles common ailments such as colds, allergies, pain and digestion, using brands like Tylenol, Nicorette and Zyrtec. Another focuses on skin, hair and sun care through names such as Neutrogena, Aveeno and OGX. A third covers teeth cleaning, baby care, feminine products and wound treatment, marketed as Listerine, Johnson's, Band-Aid and Stayfree.
Kenvue traces its start to 2022 and runs its main offices out of Skillman, New Jersey. It sits under Johnson & Johnson as a subsidiary. Trading of its stock takes place on the NYSE under the ticker KVUE.
Kenvue’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.9, in the Accumulation zone, down 6 points over five sessions.
Down 6 points over five sessions, from the Buying zone.
Reading for Sep 18, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 31 | −0.8% | −3.5% | ||
| Accumulation (current zone) | 243 | 0.0% | +1.3% | ||
| Neutral | 350 | 0.0% | −0.4% | ||
| Distribution | 37 | +0.7% | −1.2% | ||
| Selling | 1 | Too few readings yet | |||
Average KVUE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Kenvue trades 22.7% below Gekko Fair Value of $23.05, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Kenvue shares are worth, recalculated every trading day.
$23.05
Gekko Fair Value, Sep 19, 2026
22.7% Undervalued
No open-market insider purchases were filed for Kenvue, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for KVUE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in KVUE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Kenvue has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold KVUE.
Kenvue reports on Nov 2, 2026, before the open (43 days away), and beat the EPS estimate in 6 of its last 8 reports.
Nov 2, 2026
Expected before the open, 43 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.31 est $0.32 | $3.96B est $3.97B | −2.2% |
| May 7, 2026 | $0.32 est $0.26 | $3.91B est $3.84B | −0.5% |
| Feb 17, 2026 | $0.27 est $0.22 | $3.78B est $3.69B | +1.0% |
| Nov 3, 2025 | $0.28 est $0.26 | $3.76B est $3.82B | +11.1% |
| Aug 7, 2025 | $0.29 est $0.28 | $3.84B est $3.85B | −0.5% |
| May 8, 2025 | $0.24 est $0.23 | $3.74B est $3.68B | +5.8% |
| Feb 6, 2025 | $0.26 est $0.26 | $3.66B est $3.76B | −2.7% |
| Nov 7, 2024 | $0.28 est $0.27 | $3.90B est $3.92B | +5.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Kenvue is $19.50, +9.5% from the last close, from 7 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 7 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | Canaccord Genuity | — | — |
| Sep 14 | Argus Research | — | — |
| Aug 11 | UBS | $19 | +6.7% |
| Aug 7 | RBC Capital | $20 | +12.3% |
| Aug 7 | Canaccord Genuity | $18 | +1.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 19, Kenvue averaged −9.7% across the last 3 years, rising in 0 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.4% | 0 of 3 |
| Next 10 trading days | −7.1% | 0 of 3 |
| Next 15 trading days | −7.6% | 0 of 3 |
| Next 20 trading days | −9.7% | 0 of 3 |
| Next 30 trading days | −11.5% | 0 of 3 |
For scale, KVUE’s typical 20-trading-day move in either direction is about 5.2%.
Kenvue’s market cap is $34.20B, with a P/E ratio of 21 and revenue of $15.41B over the last twelve months.
Coverage of Kenvue this week reads neutral: 3 positive, 9 neutral and 1 negative headlines.
Kenvue’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| PGProcter & Gamble | Neutral | 15.8% below |
| CLColgate-Palmolive | Accumulation | 3.3% below |
| ELEstee Lauder Companies | Accumulation | 4.2% below |
| KMBKimberly-Clark | Buying | 19.5% below |
| CHDChurch & Dwight | Accumulation | 7.1% below |
| CLXClorox | Buying | 45.5% below |
A peer links to its own page where one exists.
Kenvue’s market cap is $34.20B at the Sep 18, 2026 close of $17.81, with 1.92B shares outstanding. The shares trade on a P/E ratio of 21.
The consensus analyst 12-month price target for Kenvue is $19.50, +9.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 1 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Kenvue is undervalued: the Sep 18, 2026 close of $17.81 is 22.7% below Gekko Fair Value of $23.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Kenvue is expected to report on Nov 2, 2026, before the market opens (43 days away). Analysts expect earnings of $0.28 per share on revenue of $3.86B. Kenvue beat the earnings estimate in 6 of its last 8 reports, moving 3.6% on average across the report.
Kenvue’s 52-week high is $20.13 and its 52-week low is $14.02; it closed at $17.81 on Sep 18, 2026, −2.9% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.